Cancer BiologybioRxiv
Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-low Induction of Therapy Resistance
K. A. Cotter, J. Gallon, N. Uebersax…·M. A. Rubin
The paper maps m6A in prostate cancer and shows METTL3-low promotes therapy resistance through upregulated extracellular matrix proteins and hepatocyte nuclear factor-driven gene signatures.
DOI 10.1158/1541-7786.mcr-21-0014